What drugs does MANKIND PHARMA make?

MANKIND PHARMA has 59 FDA-approved drugs including TELMISARTAN AND HYDROCHLOROTHIAZIDE, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.

What therapeutic areas does MANKIND PHARMA focus on?

MANKIND PHARMA focuses primarily on Cardiovascular and Neurology and 1 other therapeutic areas.

← Back

Data updated: Jun 28, 2026

MANKIND PHARMA

Generics

Cardiovascular Neurology Respiratory

MANKIND PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology, Respiratory.

2001

Since

Drugs

Trials

New Drugs (2yr)

Modality:

MANKIND PHARMA's Key Drugs

MANKIND PHARMA's core commercial portfolio centers on TELMISARTAN AND HYDROCHLOROTHIAZIDE, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

TELMISARTAN AND HYDROCHLOROTHIAZIDE

Cardiovascular

Hypertension

Approved 2014

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Metabolic

Approved 2025

MANKIND PHARMA's Recent FDA Approvals

MANKIND PHARMA secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

ROCURONIUM BROMIDE NDA

2025-10-24

rocuronium bromide

Routine tracheal intubation

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

ROCURONIUM BROMIDE NDA

2025-06-09

rocuronium bromide

Routine tracheal intubation

MANKIND PHARMA's Therapeutic Areas

MANKIND PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 45%

11 drugs

Neurology 20%

5 drugs

Respiratory 16%

4 drugs

Infectious Disease 12%

3 drugs

Ophthalmology 7%

1 drugs Phase 3: 1

MANKIND PHARMA's Top Competitors

MANKIND PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma

Cardiovascular, Ophthalmology, Respiratory

GE HEALTHCARE specialty

Neurology, Cardiovascular, Infectious Disease, Respiratory

Merck big-pharma

Infectious Disease, Cardiovascular, Respiratory

AbbVie big-pharma

Infectious Disease, Neurology, Ophthalmology

LEDERLE big-pharma

Infectious Disease, Respiratory, Cardiovascular, Neurology